Hematologic Malignancy
Myelodysplastic Syndrome
CI-CAN-00001247MDN · MDSExplore in graph →
Hematologic336 active trials3 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001247MDN · MDSExplore in graph →
Clinical trials
1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (307)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00652626 | Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function(RENAL) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02909972 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 55 | Aileron Therapeutics, Inc.INDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02164071 | Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies(GAH) | completed | — | 363 | CelgeneINDUSTRY | 1 | Nov 18, 2019 | clinicaltrials |
| NCT01929408 | Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients | completed | — | 703 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02719821 | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation | completed | N/A | 17 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02955043 | Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery | completed | N/A | 39 | University of Wisconsin, MadisonOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01519011 | Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine | completed | Phase 1 | 34 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00761722 | Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma(RACE) | completed | Phase 1 | 31 | CelgeneINDUSTRY | 1 | Nov 8, 2019 | clinicaltrials |
| NCT00006350 | Mycophenolate Mofetil, Tacrolimus, Daclizumab, and Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT02129101 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | completed | Phase 1 | 63 | Mayo ClinicOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00101179 | MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia | completed | Phase 1 | 63 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2019 | clinicaltrials |
| NCT00003396 | Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | 42 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT00003398 | Bone Marrow Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 4 | 45 | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT00005946 | Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation | completed | Phase 1 | — | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT00015951 | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers | completed | Phase 2 | — | University of Maryland, BaltimoreOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT03526666 | Ascorbic Acid Levels in MDS, AML, and CMML Patients | completed | — | 50 | Van Andel Research InstituteOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT00044954 | Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer | completed | Phase 2 | — | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 17, 2019 | clinicaltrials |
| NCT01305200 | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant | completed | Phase 3 | 226 | Children's Oncology GroupNETWORK | 3 | Sep 17, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT02666950 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02891551 | An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands(OCEAN) | completed | — | 209 | CelgeneINDUSTRY | 0 | Jul 24, 2019 | clinicaltrials |
| NCT00374933 | Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation | completed | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 12, 2019 | clinicaltrials |
| NCT02447666 | Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) | completed | Phase 2 | 28 | CelgeneINDUSTRY | 13 | Jul 11, 2019 | clinicaltrials |
| NCT00376480 | Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | completed | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT02920541 | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | completed | Phase 1 | 48 | Institut de Recherches Internationales ServierOTHER | 2 | May 24, 2019 | clinicaltrials |
| NCT00414310 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 153 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT01392989 | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | completed | Phase 2 | 44 | Everett MeyerOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00397579 | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01463046 | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | Phase 1 | 29 | University of California, San FranciscoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01700751 | Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation | completed | Phase 1 | 17 | Washington University School of MedicineOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01295710 | Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD) | completed | Phase 3 | 260 | Neovii BiotechINDUSTRY | 2 | Apr 9, 2019 | clinicaltrials |
| NCT00796562 | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | completed | Phase 2 | 107 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02492737 | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | completed | Phase 1 | 46 | Agios Pharmaceuticals, Inc.INDUSTRY | 2 | Mar 8, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01165996 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT00002746 | Interleukin-2 in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 | 24 | University of WashingtonOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02678338 | CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies | completed | Phase 1 | 20 | Gilead SciencesINDUSTRY | 1 | Feb 21, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02019069 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 11 | Rondeep BrarOTHER | 1 | Jan 22, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Nov 19, 2019source: clinicaltrials